Strikingly, ATP13A2 mutations are not implicated in cardiovascular but in neurodegenerative diseases, such as Parkinson’s disease (43, 44), indicating that ATP13A2 and ATP13A3 exert distinct (patho) physiological roles. This evidence concerns the gene ATP13A2 and Parkinson disease.